MGM. Lindsay Grayson

M. Lindsay Grayson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


M. Lindsay Grayson has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 June 2000
      • Vol. 4  (6) , 555-61

    Effect of anti-tuberculosis treatment on the tuberculin interferon-gamma response in tuberculin skin test (TST) positive health care workers and patients with tuberculosis.

    by R L Stuart, D Olden, P D Johnson, A Forbes, P M Bradley, J S Rothel, M L Grayson

    Public hospital, Victoria, Australia. To evaluate the effect of multidrug treatment and isoniazid (INH) chemoprophylaxis on the tuberculin interferon-y assay (QIFN) in 19 patients with culture-confirmed Mycobacterium tuberculosis and 119 health care workers (HCWs) with tuberculin skin tests (TST) > or =15 mm. Patients with M. tuberculosis were treated with standard medication and tested with QIFN at diagnosis and at regular intervals over a 12-month period. All HCWs, 59 (50%) of whom were prescribed INH chemoprophylaxis, were tested with QIFN at baseline, 2, 4, 6 and 12 months. QIFN results in patients with tuberculosis were consistent and reproducible. At the initial time point QIFN assays were positive for M. tuberculosis in 67%, and once positive, the QIFN assay remained so over the 12-month period. In the HCWS, initial QIFN assays were positive in 73 (61%). During the 12-month study, 91 HCWs had a QIFN assay on at least two occasions. The overall reproducibility between tests was fair (kappa statistic = 0.45), and was little affected by administration of INH. These data suggest that although the QIFN assay is generally positive in patients with proven tuberculosis, it does not provide clinically useful information during the first 12 months of treatment with multidrug chemotherapy or INH chemoprophylaxis.


    • 3 January 2000
      • Vol. 172  (1) , 44, 46

    Vibrio cholerae in Victoria.

    by A B Pierce, S J Broughton, P D Johnson, M L Grayson


  • Outcome of a screening program for vancomycin‐resistant enterococci in a hospital in Victoria

    by M Lindsay Grayson, Elizabeth A Grabsch, Paul D R Johnson, Dianne Olden, Melissa Aberline, H Y Li, Geoffrey Hogg, Marguerite Abbott, Peter G Kerr

    Objective To screen for faecal colonisation with vancomycin‐resistant enterococci (VRE) among potentially at‐risk patients. Design Infection control screening program. Setting Monash Medical Cen...


  • Open Access

    The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis

    by Karin Leder, John D. Turnidge, Tony M . Korman, M. Lindsay Grayson

    Since the efficacy of β-lactams against pathogens such as methicillin-susceptible Staphylococcus aureus (MSSA) is related to the time for which serum drug concentrations exceed the MIC for the pathogen, administration of anti-staphylococcal β-lactams by continuous infusion may provide a more suitable means of drug delivery than intermittent dosing. To assess the clinical efficacy of continuous-infusion therapy, we reviewed the outcomes for 20 consecutive patients with proven serious MSSA sepsis (three with endocarditis, ten osteomyelitis, one endocarditis plus osteomyelitis and six deep abscess) treated with continuous-infusion flucloxacillin (8–12 g/day). Patients initially receiving routine intermittent-dose flucloxacillin therapy were changed to continuous-infusion flucloxacillin (mean duration 29 days; range 4–60 days) for completion of their treatment course. In the majority of cases this was given at home. Serum flucloxacillin concentrations during continuous-infusion flucloxacillin 12 g/day were 11.5–>40 mg/L (ten patients) and those during continuous-infusion flucloxacillin 8 g/day were 8–>40 mg/L (five patients), these concentrations being well above the expected MIC of flucloxacillin for MSSA. Continuous-infusion flucloxacillin was well tolerated by most patients, and 14/17 patients (82%) who completed their course of continuous-infusion flucloxacillin were judged clinically and microbiologically cured at long-term follow-up (mean 67 weeks; range 4–152 weeks). These preliminary data suggest that, following initial intermittent-dose flucloxacillin therapy, continuous-infusion flucloxacillin is an effective treatment option for serious MSSA sepsis, and forms a feasible and possibly preferable alternative to glycopeptides when considering home-based parenteral therapy for these infections. Further studies are needed to identify whether continuous-infusion flucloxacillin can entirely replace intermittent-dose therapy for such infections.